Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Baxter International (NY:BAX)

33.49 +0.13 (+0.39%)
Streaming Delayed Price Updated: 1:39 PM EDT, Mar 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Baxter International

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Fresenius SE's Future With Dialysis Company Unclear, Investors Seek Answers
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite holding a 32% stake, challenges like high dialysis patient mortality and... 
Via Benzinga
Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive
From Baxter International Inc.
Via Business Wire
(BAX) - Analyzing Baxter Intl's Short Interest
Via Benzinga
Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
From Baxter International Inc.
Via Business Wire
A Glimpse Into The Expert Outlook On Baxter Intl Through 4 Analysts
Via Benzinga
Baxter to Present at Bank of America 2024 Health Care Conference
From Baxter International Inc.
Via Business Wire
Baxter Declares Quarterly Dividend
From Baxter International Inc.
Via Business Wire
Why Is Nuvo Group (NUVO) Stock Up 200% Today?
Although prenatal care specialist Nuvo Group saw its shares soar on Monday, NUVO stock faces skepticism over its SPAC merger. 
Via InvestorPlace
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses. 
Via InvestorPlace
3 Dividend Stocks For 10%+ Annual Returns
Buying undervalued dividend stocks with growth potential could lead to above-average returns. 
Via Talk Markets
Assessing Baxter Intl: Insights From 4 Financial Analysts
Via Benzinga
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Why Is Medical Device Maker Baxter Stock Trading Lower On Thursday?
Baxter reports Q1 adjusted EPS at $0.65, up 10% Y/Y, surpassing expectations. Sales hit $3.59 billion, with 2% growth on a reported basis. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BAX Stock Earnings: Baxter Intl Beats EPS, Beats Revenue for Q1 2024
BAX stock results show that Baxter Intl beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Baxter Reports First-Quarter 2024 Results
From Baxter International Inc.
Via Business Wire
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
From Baxter International Inc.
Via Business Wire
Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System
FDA clears Baxter's Novum IQ LVP & SYR infusion pumps with Dose IQ Safety Software, streamlining training & reducing cognitive burden. Explore enhanced safety features & EMR interoperability. 
Via Benzinga
Exposures Product Safety
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
From Baxter International Inc.
Via Business Wire
Baxter to Host Annual Meeting of Stockholders in Virtual Format
From Baxter International Inc.
Via Business Wire
Becton, Dickinson And Co. Dividend Stock Analysis
Becton, Dickinson, and Co. provides a wide range of medical devices and diagnostic products used in hospitals, doctors' offices, research labs, and other settings. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
Novo Nordisk's FLOW trial reveals a 24% reduction in kidney disease progression, cardiovascular events, and death with semaglutide 1.0 mg compared to placebo. Impact on dialysis stocks 
Via Benzinga
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
From Baxter International Inc.
Via Business Wire
Stock Market Commentary: “Volumes Are The Name Of The Game…”
Short, intermediate, and long term outlook on the market. Plus, a deep dive into our thesis on Cooper Standard 
Via Talk Markets
Baxter Declares Quarterly Dividend
From Baxter International Inc.
Via Business Wire
Barclays Maintains Overweight Rating for Baxter Intl: Here's What You Need To Know
Via Benzinga
Baxter Says 2023 Performance Reflects Strategic Initiatives With New Operating Model Without BioPharma Solutions Unit
Baxter's Q4 2023 results: $3.89 billion revenue, surpassing consensus, 4% Y/Y growth. Strong sales in Medical Products, Therapies, Kidney Care, and Pharmaceuticals segments. 
Via Benzinga
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
From Baxter International Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.